Importance of risk assessment in pharmaceutical excipient: An Overview

Dharshini M S[1], Jawahar Natarajan 1*, Rakshith V S[1], Arun N [1], Bhaswathi Das [1]

JSS College of Pharmacy, Ooty-643001, the Nilgiris, Tamil Nadu, India.

*Address for correspondence:
Dr. N Jawahar
Associate Professor
Department of Pharmaceutics
JSS College of Pharmacy
Ooty-643001
Contact number: +919791439545
Email: jawahar.n@jssuni.edu.in

Abstract

Excipients are an integral part of drug formulation and are used to improve drug products' safety, efficacy, and stability. They can be classified into various categories, and their selection and use must be carefully evaluated to ensure the safety and efficacy of the final product. Risk assessment is essential for evaluating the safety of excipients used in drug products. There are two main types of risk assessment: qualitative and quantitative. Qualitative risk assessment involves the identification and evaluation of potential risks associated with the use of excipients and the development of strategies to mitigate these risks. Quantitative risk assessment involves using mathematical models and data to estimate the likelihood and severity of adverse events associated with excipients. Both types of risk assessment are critical for ensuring the safety of drug products and protecting public health. This review discusses the category of the excipient used in a different dosage form, such as solid, liquid, and semisolid, and the importance of excipient risk assessment and its type

KEYWORDS: *Excipients, Risk assessment, Dosage forms, Categories*

Introduction

Excipients are non-active components added to therapeutic formulations to help in drug distribution, solubility, and stability[1]. Excipients are classified based on their physical and chemical qualities and their roles in medication formulations. These excipient types are frequently employed in solid, liquid, and semisolid dosage forms[2]. Excipients like binders, diluents, lubricants, and disintegrants are routinely employed in solid dosage forms to maintain tablet or capsule integrity, facilitate drug release, and improve bioavailability[3]. Excipients such as solvents, preservatives, and emulsifiers are frequently employed in liquid dosage forms to increase drug solubility, stability, and efficacy[4]. Excipients such as gelling agents, emulsifiers, and penetration enhancers are often employed in semisolid dosage forms to optimize medication absorption and delivery[5].

To ensure safety, efficacy, and compatibility with other excipients and pharmacological ingredients, excipients for drug formulations must undergo a comprehensive evaluation. Adverse drug responses or reduced drug efficacy may result from ineffective excipients or excipients that have not undergone enough safety and efficacy testing [6].

Regulatory organizations like the FDA and EMA have set standards for using excipients in medication formulations to assure the safety and efficacy of those formulations [7]. These recommendations offer manufacturers a framework for choosing suitable excipients and performing risk analyses to assess the efficacy and safety of excipients in medication formulations [8].

Excipient risk assessment entails assessing the safety and efficacy of excipients used in medicinal formulations. The risk assessment process involves identifying potential hazards connected with excipients, assessing the likelihood and severity of these hazards, and developing risk mitigation or elimination methods[9].

Excipient risk evaluation considers several factors, including the excipient's intended use, physical and chemical characteristics, and potential interactions with other excipients and pharmacological components. Typically, risk assessment is done by combining qualitative and quantitative techniques[10].

A vital component of medication formulation and development is excipient risk assessment. Excipients used in therapeutic formulations are evaluated for their efficacy and safety, and potential dangers are identified along with mitigation or risk-reduction measures. Manufacturers must follow regulatory requirements and conduct in-depth risk analyses to ensure patient safety and therapeutic efficacy.[11]

Role of Excipients and Properties in the pharmaceutical products

Excipients have different roles in a formulation

- Assist with the manufacturing of the drug delivery device.
- safeguard, support, or improve stability, bioavailability, or patient acceptability
- Assist in product identification and improve any aspect of overall safety
- Contribute to the effectiveness and delivery of the drug in use
- Contribute to the integrity of the drug product during storage [12]

Properties of Excipient

Excipients should have the following properties

- There are no pharmacological effects.
- Cost-effective.
- Comply with regulatory mandates.
- Chemically and physiologically stable.

Categorization of excipient

Pharmaceutical excipients can be categorized in different ways



Route of administration	**By origin**	**By Functionality**
Oral Excipients	Marine Origin	Binders and fillers
Local action Excipients	Animal Origin	Excipient for direct compression
Parenteral Excipients	Inorganic Chemicals	
Other Excipients	Synthetic Semisynthetic	

Excipients in different dosage forms

Excipients are used in various forms of drug products to serve different purposes. Here are some examples of commonly used excipients in solid, liquid, and semisolid dosage forms[3]:

Excipients in solid dosage form

1. **Diluents/Fillers**: Diluents are used to increase the bulk of the formulation and help in the manufacturing process by improving the flow properties of the powder blend.[12]
2. **Binders**: Binders hold the active ingredients and other excipients together to form a cohesive tablet or capsule [13].
3. **Disintegrants**: Disintegrants are added to the formulation to promote the breakup of the tablet or capsule in the gastrointestinal tract, allowing for the release of the active ingredients[14].
4. **Lubricants**: Lubricants are added to reduce friction between particles, thereby improving the flowability of the powder blend and reducing the likelihood of the tablet or capsule sticking during manufacturing[15].
5. **Glidants**: Glidants are used to improve the flow properties of the powder blend and reduce the likelihood of segregation during manufacturing[16].

6. **Coatings**: Coatings provide a protective layer to the tablet or capsule, improve the appearance and ease of swallowing, and mask unpleasant tastes or odors[17].
7. **Colorants**: Colorants provide color to the tablet or capsule, improve the appearance, and help distinguish between different strengths or types of medications[18].
8. **Sweeteners**: Sweeteners are added to mask the unpleasant taste of some medications, making them easier to swallow[19].
9. **Preservatives** are added to maximize the shelf-life of the medication and protect against microbial contamination[20].
10. **Solubilizers**: Solubilizers are added to extend the solubility of BCS class four drugs, allowing for improved absorption and bioavailability[21].
11. **Antioxidants**: Antioxidants are added to prevent the degradation of the drug due to oxidation, thereby increasing its shelf life[22].
12. **Buffers**: Buffers are added to maintain the pH of the formulation within a specific range to ensure stability and prevent degradation of the drug[23].
13. **Antiadherents**: Antiadherents are used to prevent the adhesion of the tablet or capsule to the punch or die during manufacturing[24].
14. **Emulsifiers**: Emulsifiers improve the stability of emulsions, suspensions, and other formulations containing two immiscible phases[25].
15. **Flavorings**: Flavorings are added to improve the taste of the formulation and make it more palatable[26].
16. **Humectants**: Humectants prevent the formulation from drying out or becoming too hard, improving its stability and ease of administration.[27]
17. **Glazing agents**: These agents provide a glittering appearance to the tablet or capsule and protect it from moisture[28].
18. **Opacifying agents**: Opacifying agents are added to make the formulation opaque, thereby improving its appearance and masking the color or appearance of the drug substance[29].

Excipients in liquid dosage form

1. **Solvents**: Solvents dissolve or disperse the active ingredient(s) and other excipients in the formulation. Common solvents in liquid dosage forms include water, alcohol, and glycerin.
2. **Surfactants**: Surfactants are used to reduce the surface tension of the liquid and improve the solubility and dispersion of the active ingredient(s) and other excipients in the solvent. They are also used to stabilize emulsions and suspensions. Common surfactants in liquid dosage forms include polysorbate 80, sodium lauryl sulfate, and lecithin.
3. **Viscosity enhancers**: Viscosity enhancers are used to increase the thickness and consistency of the liquid dosage form, making it easier to administer and improving its stability. Common viscosity enhancers include cellulose derivatives, such as methylcellulose and hydroxyethylcellulose, and natural gums, such as Xanthan gum and Guar gum.
4. **Preservatives**: Preservatives are added to liquid dosage forms to prevent microbial growth and extend their shelf life. Common preservatives in liquid dosage forms include benzalkonium chloride, phenol, and methylparaben.
5. **Antioxidants**: Antioxidants are added to liquid dosage forms to prevent oxidation of the active ingredient(s) and other excipients, which can cause degradation and reduce the efficacy of the

medication. Common antioxidants used in liquid dosage forms include ascorbic acid, tocopherol, and butylated hydroxyanisole (BHA).

6. **Buffers**: Buffers are used to maintain the pH of the liquid dosage form within a specific range, which can improve the stability and solubility of the active ingredient(s) and other excipients. Common buffers in liquid dosage forms include sodium phosphate, citric acid, and sodium acetate.
7. **Flavorings and sweeteners**: Flavorings and sweeteners are added to liquid dosage forms to improve the taste and make them more palatable. Common flavorings and sweeteners used in liquid dosage forms include sucrose, fructose, and artificial flavors.
8. **Colorants**: Colorants are added to liquid dosage forms to improve their appearance and to distinguish between different strengths or types of medication. Common colorants in liquid dosage forms include FD&C dyes and natural colorings, such as caramel.
9. **Chelating agents**: Chelating agents are used to sequestering metal ions that can cause oxidation and degradation of the active ingredient(s) and other excipients. Common chelating agents in liquid dosage forms include ethylenediaminetetraacetic acid (EDTA) and citric acid.
10. **Emulsifiers**: Emulsifiers stabilize oil-in-water or water-in-oil emulsions in Parental dosage forms. Common emulsifiers used in parental dosage forms include polysorbate 20 and 80, lecithin, and sorbitan esters[30].

Excipients in semi-dosage form

1. **Emollients**: Emollients are used to soften and soothe the skin and to improve the spreadability of the semisolid dosage form. Common emollients in semisolid dosage forms include petrolatum, mineral oil, and lanolin[31].
2. **Emulsifiers**: Emulsifiers stabilize oil-in-water or water-in-oil emulsions in semisolid dosage forms. Common emulsifiers in semisolid dosage forms include polysorbate 20 and 80, lecithin, and sorbitan esters[32].
3. **Viscosity enhancers**: Viscosity enhancers are used to increase the thickness and consistency of the semisolid dosage form, making it easier to apply and improving its stability. Common viscosity enhancers include cellulose derivatives, such as methylcellulose and hydroxyethylcellulose, and natural gums, such as Xanthan gum and Guar gum[33].
4. **Penetration enhancers**: To make the semisolid dosage form more permeable and facilitate easier skin penetration of the active ingredient(s), penetration enhancers are utilized. Propylene glycol and dimethyl sulfoxide (DMSO) are frequent penetration enhancers in semisolid dose formulations.[34].
5. **Preservatives**: Preservatives are added to semisolid dosage forms to inhibit microbial development and extend shelf life. Preservatives commonly used in semisolid dose forms include benzalkonium chloride, phenol, and methylparaben.[35].
6. **Antioxidants**: These are added to semisolid dosage forms to inhibit oxidation of the active ingredient(s) and other excipients, which can cause degradation and reduce the efficacy of the medication. Common antioxidants in semisolid dosage forms include ascorbic acid, tocopherol, and butylated hydroxyanisole (BHA)[36].
7. **Humectants**: Humectants prevent the semisolid dosage form from drying out and improve its moisture retention. Common humectants used in semisolid dosage forms include glycerin and propylene glycol[27].

8. **Thickeners**: Thickeners are used to increase the viscosity and improve the spreadability of the semisolid dosage form. Common thickeners in semisolid dosage forms include stearic acid and cetyl alcohol[37].
9. **Colorants**: These are added to semisolid dosage forms to improve their appearance and to distinguish between different strengths or types of medication. Common colorants in semisolid dosage forms include FD&C dyes and natural colorings, such as caramel[38].

How excipients affect the drug product

An excipient's physicochemical and mechanical qualities are known to influence the final drug product's quality, performance, or processing. Excipient properties often exhibit varying degrees of intrinsic or 'natural' variability due to changes in starting ingredients and excipient manufacturing. The criticality of certain qualities is usually established by their importance to the function of a specific excipient. The importance of a certain excipient trait is frequently characterized by its potential impact on therapeutic product quality, which API, formulation, and process factors influence. As a result, evaluating the critical features of an excipient must be based on knowledge of the excipient as well as the API, product, and process[39].

When certain excipient qualities have been found to affect the potency, purity, or even processing of a certain product (e.g., pH, moisture, residual metals, or peroxides), high excipient variability might be harmful. When consistent features of functional excipients are critical to establishing reproducible product performance and quality, such as modified release (MR) or amorphous solid dispersion (ASD) goods, this variability can be harmful.

[40]. The extent of an excipient's inherent variability from supplier to supplier and batch to batch is frequently determined by variations in the starting raw materials (e.g., source, specifications), manufacturing technology (e.g., batch vs. continuous processing), process parameters and controls, scale, equipment, systems, operators, environmental conditions, and even characterization tests (e.g., sensitivity, selectivity). The origin of an excipient (natural, naturally derived, synthetic, or semisynthetic) is often important in its intrinsic variability. For example, feedstock for organically generated polymeric excipients can vary depending on crop type, growth conditions, and harvesting region. Batch blending is sometimes required to achieve product criteria due to broader natural variance, resulting in bigger composition fluctuations [41]. On the other hand, synthetic excipients are made from purer starting compounds and have lesser variability when manufacturing is tightly regulated. For example, the variation in leftover starting materials, byproducts, or synthetic contaminants is more common, while excipient characteristics can still fluctuate[42]. The impact of an excipient's characteristics can also affect how robustly a product's formulation, manufacturing process, and even test procedures are to excipient variability.

How excipient qualities affect drug product performance and critical quality attributes (CQAs) strongly depends on the excipient's function in the formulation and the interaction between excipient quality and the drug product. Variability in rate-controlling polymers for MR products, for example, can significantly impact drug-release performance and reproducibility; however, dissolution performance of an immediate-release product containing soluble API is often capable of tolerating greater variability in an excipient used as a processing aid or diluent[43]. Depending on the API, product design, and manufacturing process, the impact of an excipient's chemical (e.g., substitution, trace impurities) and physical (e.g., particle size,

flowability) qualities on product CQAs may also vary. For example, a medicine prone to hydrolysis may be stable regardless of pH or moisture content changes but not residual peroxide levels. In contrast, the opposite may be true for a different drug that largely degrades by oxidation. Despite changes in apparent viscosity and polymer substitutions remaining within specifications, drug release from an extended-release product may show significant variance between rate-controlling polymer batches or suppliers[44]. This variability could explain variability in excipient qualities that can affect drug-release performance but are not regulated by specifications, such as polydispersity or substitution homogeneity. Excipient characteristics and interactions with certain processes or unit activities can also impact medicinal product processability or quality. Variability in the glass transition temperature of a polymer used to make ASD utilizing a hot-melt extrusion technique, for example, may impair the extrusion process repeatability and residual crystallinity[45]. However, the spray-drying process would be more forgiving of this variability.

Importance of risk assessment for excipients

Excipient risk assessment entails assessing the potential risks associated with the excipient use of drug products, such as the likelihood and severity of adverse events and the potential influence on patient safety and product quality.[46]It is essential to conduct risk assessments for excipients to ensure that they are safe for use in drug products and that their use does not compromise the safety or efficacy of the drug.

Some of the reasons why risk assessment for excipients is important to include:

Safety: Excipients such as allergic reactions or toxicity can harm patient safety. Risk assessments help identify potential safety issues before they become a problem.

Quality: Excipients can impact the quality of drug products, including stability, efficacy, and appearance. Risk assessments help ensure that the use of excipients does not compromise the quality of the drug.

Regulatory compliance: Regulatory agencies require that risk assessments be conducted for excipients in drug products. Failure to conduct a proper risk assessment can result in delays in regulatory approval or the withdrawal of the drug from the market[47].

Cost-effectiveness: Risk assessments can help identify potential problems early in the drug development process, saving time and money in the long run by avoiding costly product recalls or re-formulations.

Overall, risk assessment for excipients is critical for ensuring patient safety, product quality, regulatory compliance, and cost-effectiveness. By conducting proper risk assessments, pharmaceutical companies can ensure that the excipients they use are safe and effective and that their drug products meet the highest quality and regulatory compliance standards.

Here are the key steps involved in conducting a risk assessment for excipients:

1. Identify the excipient: The first step in an excipient risk evaluation is identifying the excipient utilized in the drug product. This involves gathering information about the excipient's physical and chemical properties, including its composition, intended use, and potential interactions with other ingredients in the drug product.
2. Hazard identification: The next step is to identify the potential hazards associated with the use of the excipient in the drug product. This involves reviewing available data on the excipient's toxicity, the potential for allergic reactions, and other safety concerns.

3. Exposure assessment: The next step is to assess the potential exposure of patients to the excipient. This involves evaluating the dose of the excipient in the drug product, the route of administration, and the frequency and duration of use.
4. Risk characterization: Based on the hazard identification and exposure assessment, The next stage is to define the level of risk associated with the drug product's usage of the excipient. This entails assessing the likelihood and severity of adverse events caused by the excipient.
5. Risk management: The next step is to create risk management strategies to reduce any risks that have been identified based on the risk characterization. This may include modifying the formulation to reduce the amount or frequency of excipient use, implementing additional safety measures such as product labeling or monitoring patient safety, or selecting an alternative excipient that poses less risk.

Conducting a risk assessment for excipients is essential to ensure the safety and efficacy of drug products. Following a systematic approach, pharmaceutical companies can identify potential risks early in drug development and develop risk management strategies to ensure patient safety and product quality[48].

Types of risk assessment

Depending on the specific issues and assessment objectives, different forms of risk assessments can be carried out for excipients. Here are some of the prevalent excipient risk assessment types:

Quality risk assessment: This type of risk assessment is focused on evaluating the potential risks to product quality that may arise from using an excipient. Quality risk assessments may include evaluating the potential for impurities or contaminants to be present in the excipient and the excipient's potential impact on product stability, efficacy, or safety.

Safety risk assessment: Safety risk assessments focus on evaluating the potential risks to patient safety that may arise from using an excipient. Safety risk assessments may include evaluating the potential for allergic reactions, toxicity, or other adverse effects of the excipient[49].

Supply chain risk assessment: Supply chain risk assessments evaluate the potential risks associated with the supply and use of an excipient, including risks related to the quality and reliability of the supply chain and risks related to regulatory compliance[50].

Environmental risk assessment: Environmental risk assessments evaluate the potential environmental risks that may arise from using or disposing of an excipient. This type of assessment may include evaluating the potential for the excipient to be toxic to aquatic or plant life and the potential for the excipient to accumulate in the environment.

Legal and regulatory risk assessment: Legal and regulatory risk assessments evaluate the potential risks associated with non-compliance with regulatory requirements or other legal obligations related to using an excipient. This may include evaluating the potential for fines or other penalties and the potential impact on the company's reputation or brand.

Quantitative and qualitative risk assessments

Both quantitative and qualitative risk assessments can be used to evaluate the potential risks associated with the use of excipients in drug products. Here is a brief overview of each approach:

Quantitative risk assessment:

Quantitative risk assessment involves using mathematical models to assess the probability and severity of adverse events or outcomes of using an excipient. This approach typically requires a significant amount of data on the characteristics and properties of the excipient, as well as information on its potential impact on the drug product and its intended use. Methods for quantitative risk assessment include fault tree analysis (FTA), event tree analysis (ETA), hazard analysis, and critical control points (HACCP).

Qualitative risk assessment:

Qualitative risk assessment involves a more subjective evaluation of the potential risks associated with using an excipient based on expert judgment, historical data, or other qualitative information. This approach is often used when limited data is available on the excipient or when the potential risks are difficult to quantify. Qualitative risk assessment typically involves identifying and evaluating potential hazards or risks associated with the excipient and the likelihood and severity of adverse events or outcomes. Some examples of qualitative risk assessment methods include hazard identification, risk ranking and filtering, and expert elicitation[51].

Both quantitative and qualitative risk assessment approaches can be useful in evaluating the potential risks associated with the use of excipients in drug products. The specific approach will depend on the available data, the complexity of the system, and the desired level of detail and accuracy.

Various quantitative risk assessment methods can be used to evaluate the potential risks associated with using excipients in drug products. Here are a few examples:

1. **Hazard analysis and critical control points (HACCP):** HACCP is a popular strategy for identifying and managing possible hazards in the food and pharmaceutical industries. HACCP is a systematic strategy for detecting hazards connected with using excipients in pharmaceutical products and developing controls to prevent or reduce those hazards.
2. **Fault tree analysis (FTA):** FTA is a method for analyzing and evaluating the potential risks associated with complex systems. FTA involves developing a logical model of the system and using probability calculations to evaluate the likelihood of specific failure scenarios. FTA can be used to identify potential hazards associated with using excipients in drug products and evaluate the effectiveness of risk mitigation strategies.
3. **Event tree analysis (ETA**): ETA is similar to FTA but focuses on the events that could lead to a specific outcome or hazard. When developing risk-reduction plans, ETA can be used to assess the likelihood and severity of adverse events linked to the use of excipients in pharmaceutical products.
4. **Monte Carlo simulation:** Monte Carlo simulation involves using random sampling to model the behavior of complex systems. Monte Carlo simulation can evaluate the potential risks of using excipients in drug products by simulating different scenarios and assessing the likelihood and severity of adverse events.

These quantitative risk assessment methods can help identify and evaluate potential risks associated with using excipients in drug products. The specific method used will depend on the complexity of the system, the available data, and the desired level of detail and accuracy[52].

The possible dangers connected to using excipients in pharmaceutical products can be assessed using various qualitative risk assessment techniques. Several of these techniques include:

1. **Hazard Analysis and Critical Control Points (HACCP):** This is a systematic approach to identifying potential hazards and implementing measures to prevent or control them.
2. **Failure Mode and Effects Analysis (FMEA)**: is a technique used to pinpoint potential failure modes, assess their ramifications, and create plans to avert or lessen these failures.
3. **Fault Tree Analysis (FTA)**: In order to establish plans to avoid or lessen potential failure situations and their causes, this strategy is utilized.
4. **Risk Ranking and Filtering (RRF):** This method is used to rank and prioritize risks based on their potential impact and likelihood and filter out low-risk scenarios.
5. **Bowtie Analysis**: This method is used to visualize potential hazards and their consequences and identify preventive and mitigating measures.

Each of these approaches has advantages and disadvantages, and the particular requirements and conditions of the risk assessment will determine the best approach. In general, qualitative risk assessment methods are useful for assessing the potential risks associated with using excipients in drug products and identifying appropriate risk management strategies[52,53].

Conclusion

In conclusion, excipients are essential in formulating pharmaceutical products in various dosage forms, such as solid, parenteral, and semisolid. In solid dosage forms, commonly used excipient categories enhance the physical properties of the formulation, such as its compressibility and flowability, and improve the disintegration and dissolution properties. In liquid dosage forms, commonly used excipient categories help improve the active ingredient's stability and solubility, enhance its taste and palatability, and ensure accurate dosing. In semisolid dosage forms, commonly used excipient categories These excipients help improve the formulation's stability and consistency, enhance its spreadability and texture and facilitate the penetration and absorption of the active ingredient. The selection and use of appropriate excipient categories are essential for optimizing pharmaceutical formulations' safety, efficacy, and quality. Risk assessment for excipients is a crucial step in the pharmaceutical development process. It is essential to ensure the successful development and commercialization of pharmaceutical products in solid, liquid, and semisolid dosage forms. For pharmaceutical products to be safe and effective, excipient risk assessments must be qualitative and quantitative. The outcomes of these analyses assist in selecting and using suitable excipients and support the creation of reliable pharmaceutical formulations. For pharmaceutical products to be safe and effective and protect the public's health, comprehensive risk assessments of excipients are essential.

REFERENCE

1. Patel R, Barker J, ElShaer A. Pharmaceutical excipients and drug metabolism: a mini-review. Int J Mol Sci. 2020;21(21):8224.
2. philippe. Roles of Excipients [Internet]. Pharma Excipients. 2019 [cited 2023 Apr 18]. Available from: https://www.pharmaexcipients.com/news/roles-of-excipients/
3. van der Merwe J, Steenekamp J, Steyn D, Hamman J. The Role of Functional Excipients in Solid Oral Dosage Forms to Overcome Poor Drug Dissolution and Bioavailability. Pharmaceutics. 2020 Apr 25;12(5):393.
4. Buckley LA, Salunke S, Thompson K, Baer G, Fegley D, Turner MA. Challenges and strategies to facilitate formulation development of pediatric drug products: Safety qualification of excipients. Int J Pharm. 2018;536(2):563–9.
5. Shostak TA, Bilous SB, Kalynyuk TG. Features of the excipients selection for semisolid dosage forms. Фармацевтичний Часопис. 2015;(1).
6. Abrantes CG, Duarte D, Reis CP. An overview of pharmaceutical excipients: safe or not safe? J Pharm Sci. 2016;105(7):2019–26.
7. Kirchhoff CF, Wang XZM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114(12):2696–705.
8. Ionova Y, Wilson L. Biologic excipients: Importance of clinical awareness of inactive ingredients. PLoS One. 2020;15(6):e0235076.
9. Ruban O, Pidpruzhnykov Y, Kolisnyk T. Excipient risk assessment: possible approaches to assessing the risk associated with excipient function. J Pharm Investig. 2018;48:421–9.
10. Kozarewicz P, Loftsson T. Novel excipients–Regulatory challenges and perspectives–The EU insight. Int J Pharm. 2018;546(1–2):176–9.
11. Carter D. Risk assessment for excipients for enhanced patient safety. Pharm Technol. 2011;35:s29–33.
12. Haywood A, Glass BD. Pharmaceutical excipients–where do we begin? Aust Prescr. 2011;34(4).
13. Chaudhari SP, Patil PS. Pharmaceutical excipients: a review. Int J Adv Pharm Biol Chem. 2012;1(1):21–34.
14. Remya KS, Beena P, Bijesh PV, Sheeba A. Formulation development, evaluation and comparative study of effects of super disintegrants in cefixime oral disintegrating tablets. J Young Pharm. 2010;2(3):234–9.
15. Morin G, Briens L. The effect of lubricants on powder flowability for pharmaceutical application. Aaps Pharmscitech. 2013;14:1158–68.
16. Meyer K, Zimmermann I. Effect of glidants in binary powder mixtures. Powder Technol. 2004;139(1):40–54.
17. Salawi A. Pharmaceutical Coating and Its Different Approaches, a Review. Polymers. 2022;14(16):3318.
18. Šuleková M, Smrčová M, Hudák A, Heželová M, Fedorová M. Organic colouring agents in the pharmaceutical industry. Folia Vet. 2017;61(3):32–46.
19. Almurisi SH, Akkawi ME, Chatterjee B, Sarker MZI. Taste masking of paracetamol encapsulated in chitosan-coated alginate beads. J Drug Deliv Sci Technol. 2020;56:101520.

20. Preservative - an overview | ScienceDirect Topics [Internet]. [cited 2023 Apr 18]. Available from: https://www.sciencedirect.com/topics/medicine-and-dentistry/preservative
21. Sareen S, Mathew G, Joseph L. Improvement in solubility of poor water-soluble drugs by solid dispersion. Int J Pharm Investig. 2012;2(1):12.
22. Zehiroglu C, Ozturk Sarikaya SB. The importance of antioxidants and place in today's scientific and technological studies. J Food Sci Technol. 2019;56:4757–74.
23. Sek D. Breaking old habits: moving away from commonly used buffers in pharmaceuticals. Eur Pharm Rev. 2012;3.
24. Excipient [Internet]. [cited 2023 Apr 18]. Available from: https://www.bionity.com/en/encyclopedia/Excipient.html
25. Khan BA, Akhtar N, Khan HMS, Waseem K, Mahmood T, Rasul A, et al. Basics of pharmaceutical emulsions: A review. Afr J Pharm Pharmacol. 2011;5(25):2715–25.
26. Sohi H, Sultana Y, Khar RK. Taste masking technologies in oral pharmaceuticals: recent developments and approaches. Drug Dev Ind Pharm. 2004;30(5):429–48.
27. Humectant - an overview | ScienceDirect Topics [Internet]. [cited 2023 Apr 18]. Available from: https://www.sciencedirect.com/topics/medicine-and-dentistry/humectant
28. Raising agents, glazing agents and sequesterants for the food industry – Food Additives and Food Quality Assurance [Internet]. [cited 2023 Apr 18]. Available from: https://ebooks.inflibnet.ac.in/ftp03/chapter/raising-agents-glazing-agents-and-sequesterants-for-the-food-industry/
29. Opacifier - an overview | ScienceDirect Topics [Internet]. [cited 2023 Apr 18]. Available from: https://www.sciencedirect.com/topics/materials-science/opacifier
30. Kumar M. A Comprehensive Review on Pharmaceutical Liquid Dosage Form. 2022;
31. Purnamawati S, Indrastuti N, Danarti R, Saefudin T. The role of moisturizers in addressing various kinds of dermatitis: a review. Clin Med Res. 2017;15(3–4):75–87.
32. Emulsifying Agent - an overview | ScienceDirect Topics [Internet]. [cited 2023 Apr 18]. Available from: https://www.sciencedirect.com/topics/medicine-and-dentistry/emulsifying-agent
33. Gelling Agent - an overview | ScienceDirect Topics [Internet]. [cited 2023 Apr 18]. Available from: https://www.sciencedirect.com/topics/medicine-and-dentistry/gelling-agent
34. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2012;64:128–37.
35. Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. J Pharm Sci. 2007;96(12):3155–67.
36. Lourenço SC, Moldão-Martins M, Alves VD. Antioxidants of Natural Plant Origins: From Sources to Food Industry Applications. Molecules. 2019 Nov 15;24(22):4132.
37. Barnes TM, Mijaljica D, Townley JP, Spada F, Harrison IP. Vehicles for drug delivery and cosmetic moisturizers: Review and comparison. Pharmaceutics. 2021;13(12):2012.
38. Allam KV, Kumar GP. Colorants-the cosmetics for the pharmaceutical dosage forms. Int J Pharm Pharm Sci. 2011;3(3):13–21.
39. Dave VS, Saoji SD, Raut NA, Haware RV. Excipient variability and its impact on dosage form functionality. J Pharm Sci. 2015;104(3):906–15.
40. Kar M, Chourasiya Y, Maheshwari R, Tekade RK. Current developments in excipient science: implication of quantitative selection of each excipient in product development. In: Basic fundamentals of drug delivery. Elsevier; 2019. p. 29–83.

41. Beneke CE, Viljoen AM, Hamman JH. Polymeric plant-derived excipients in drug delivery. Molecules. 2009;14(7):2602–20.
42. Lay Peng Soh J, Valeria Liew C, Wan Sia Heng P. Impact of excipient variability on drug product processing and performance. Curr Pharm Des. 2015;21(40):5890–9.
43. Govender R, Kissi EO, Larsson A, Tho I. Polymers in pharmaceutical additive manufacturing: A balancing act between printability and product performance. Adv Drug Deliv Rev. 2021;177:113923.
44. Waterman KC, Adami RC, Alsante KM, Hong J, Landis MS, Lombardo F, et al. Stabilization of pharmaceuticals to oxidative degradation. Pharm Dev Technol. 2002;7(1):1–32.
45. Zarmpi P, Flanagan T, Meehan E, Mann J, Fotaki N. Biopharmaceutical aspects and implications of excipient variability in drug product performance. Eur J Pharm Biopharm. 2017;111:1–15.
46. Pidpruzhnykov Y, Kolisnyk T, Ruban O. A new method for risk assessment of pharmaceutical excipients. Pharm Technol. 2018;42(3):38–44.
47. Holtz F. EU Excipient Risk Assessment Guidelines – Practical Implementation Experience.
48. Aven T. Risk assessment and risk management: Review of recent advances on their foundation. Eur J Oper Res. 2016;253(1):1–13.
49. Faustman EM, Omenn GS. Risk assessment. Casarett Doull's Toxicol Basic Sci Poisons. 2008;107–28.
50. Ho W, Zheng T, Yildiz H, Talluri S. Supply chain risk management: a literature review. Int J Prod Res. 2015;53(16):5031–69.
51. Tang CS. Perspectives in supply chain risk management. Int J Prod Econ. 2006;103(2):451–88.
52. Teixeira A, Sou KC, Sandberg H, Johansson KH. Secure control systems: A quantitative risk management approach. IEEE Control Syst Mag. 2015;35(1):24–45.
53. Quantifying risk [Internet]. [cited 2023 Apr 18]. Available from: https://www.pmi.org/learning/library/quantitative-risk-assessment-methods-9929